Atlas Trials

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Clinical trial NCT05658003 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05658003
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Start date
2023-05-05
Primary completion
2024-12-02
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.